Listed by the USPTO as KAMM, JUDITH MARIE
Tech Center 1600 • Art Units: 1611 1626 1641 1658
This examiner grants 43% of resolved cases
KAMM, JUDITH MARIE is assigned to tech center 1600 and art unit 1611. Her profile records 63 resolved cases, an allowance rate of 42.9%, and a median of 1437 days to allowance. Interviews are associated with a 57.1% lift in the recorded allowance rate. The contrast between the allowance figure and interview measure makes interview practice a notable consideration for applicants.
Symrise AG, Purdue Research Foundation, and Cmpd Licensing LLC are the listed companies. The listed firms are MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, Blank Rome LLP, and FULLER IP LAW LLC. The resolved-case base supports directional analysis but remains smaller than a large examination record. Counsel may consider interviews early, with preparation directed toward addressing the issues driving prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18618262 | LIQUID EMBOLIC MATERIALS | Final Rejection | Boston Scientific Scimed, Inc. |
| 19039128 | HAIR CARE COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18719997 | Composition | Final Rejection | Syngenta Crop Protection AG |
| 18013508 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | Final Rejection | The Regents of the University of California |
| 18741947 | HAIR VOLUMIZING SYSTEM USING CHITOSAN COMPLEX FOR LONG-LASTING EFFECT | Final Rejection | Henkel AG & Co. KGaA |
| 18562601 | PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE AMORPHOUS SOLID SOLUTIONS AND DISPERSIONS | Non-Final OA | The Texas A&M University System |
| 18569924 | MODIFICATION OF PLANT MESSENGER PACKS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18984124 | PHOTOACTIVATABLE NANOPARTICLES AND USES THEREOF AS AGENTS FOR IMMUNOTHERAPY COMBINATIONS | Non-Final OA | Board of Regents, The University of Texas System |
| 17972972 | PLASTICIZERS TO IMPROVE RELEASE PERFORMANCE OF AMORPHOUS SOLID DISPERSIONS | Final Rejection | Purdue Research Foundation |
| 17233594 | SKELETAL MUSCLE REGENERATION IN VOLUMETRIC MUSCLE LOSS USING BIOMIMETIC GLYCOSAMINOGLYCAN-BASED HYDROGEL | Non-Final OA | Purdue Research Foundation |
| 18041618 | NANOPARTICULATE SYSTEM FOR TREATING ORAL CANCER | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18708433 | LONG-ACTING INJECTABLE IN SITU FORMING BIODEGRADABLE IMPLANTS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | Non-Final OA | University of Connecticut |
| 18950187 | THUMBTACK NEEDLE DRESSING FOR HEMOSTASIS AFTER OPERATION | Non-Final OA | Shanghai Sixth People's Hospital |
| 18031583 | COMPOSITION | Non-Final OA | Givaudan SA |
| 18833384 | New Coolants, and Preparations Containing Same | Non-Final OA | Symrise AG |
| 18301051 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | Non-Final OA | Symrise AG |
| 18009295 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | Final Rejection | Symrise AG |
| 18837556 | BIODEGRADABLE, NON-POROUS MEDICAL DEVICE AND METHODS FOR MAKING AND USING THE SAME | Non-Final OA | OCTAPHARMA AG |
| 17625825 | BIOPOLYMER-BASED MENISCUS IMPLANT | Final Rejection | Shu-Tung and Alice Li Foundation Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy42.9% of resolved applications examined by Judith Marie Kamm were allowed (63 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +57.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Judith Marie Kamm took 1,437 days on average from filing to allowance.
Judith Marie Kamm examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
